Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Earlier may be better for neurostimulation in Parkinson’s

Adding neurostimulation to best medical therapy boosts quality of life in patients with relatively early-stage Parkinson’s disease, shows a randomized trial.

18 Feb 2013

MILabs VECTor/CT installed by Molecular Imaging Center Antwerp (MICA) in Belgium

MILabs B.V. is pleased to announce that the Molecular Imaging Center Antwerp (MICA) in Belgium has installed a MILabs VECTor/CT to enhance their portfolio of pre-clinical nuclear oncology and neurology imaging and research capabilities.

18 Feb 2013

Scientists discover new subgroups of GC patients with different disease's characteristics

A collaboration between Portuguese and Italian scientists has discovered new subgroups of stomach cancer patients with different disease's characteristics, an information that is hoped will help improving the clinical management of a disease that still kills a dismaying 3 out of 4 patients.

18 Feb 2013

Shorter version of abPG-SGA can potentially improve outcomes for cancer patients

Considering the many things a cancer patient has to think about, it's easy to understand why maintaining proper nutrition may not be top of mind. This can be true, too, at busy outpatient settings where it's often difficult to find the time and resources to test cancer patients for malnutrition.

18 Feb 2013

Colorectal cancer outcomes could be improved with regular genetic screening for Lynch syndrome

Cleveland Clinic researchers have found that colorectal cancer outcomes could be improved with regular genetic screening for Lynch syndrome, the most common hereditary, adult-onset cause of colorectal cancer, as published in the online version of the Journal of Clinical Oncology.

16 Feb 2013

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).

16 Feb 2013

Overall rise in drug costs is less than in previous years

Even though costs for medications will continue to rise in 2013 by as much as 4 percent, the increase is projected to be less than in previous years, according to a report in the advance online publication of the American Journal of Health-System Pharmacy, the journal of the American Society of Health-System Pharmacists (ASHP).

16 Feb 2013

Government of Québec announces $10M investment in Personalized Medicine Partnership for Cancer

The Government of Québec announced today a $10 million investment in the Personalized Medicine Partnership for Cancer (PMPC).

16 Feb 2013

New approach could make gene therapy dramatically more effective for HIV patients

A research team from Case Western Reserve University School of Medicine has discovered an approach that could make gene therapy dramatically more effective for patients.

16 Feb 2013

IKBKE gene plays a key role in tobacco-induced lung cancer

Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.

16 Feb 2013

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.

15 Feb 2013

Selumetinib shrinks tumors in women with low-grade ovarian cancer

Researchers at The University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib.

15 Feb 2013

Patient-specific cancer cell lines designed to predict chemotherapy sensitivity

In laboratory studies, scientists at the Johns Hopkins Kimmel Cancer Center have developed a way to personalize chemotherapy drug selection for cancer patients by using cell lines created from their own tumors.

15 Feb 2013

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood. Now, Mayo Clinic researchers have found out why this happens.

15 Feb 2013

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).

15 Feb 2013

Third Rock Ventures announces formation of Jounce Therapeutics

Third Rock Ventures, LLC today announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is focused on the discovery and development of first-in-class cancer immunotherapies designed to harness the patient's immune system to seek out and attack cancerous cells and tumors.

15 Feb 2013

Castle Biosciences launches MyUvealMelanoma website

Castle Biosciences Inc., a leading developer of prognostic tests for rare cancers, announced today the launch of MyUvealMelanoma.com, a website created to educate newly diagnosed patients, their families and healthcare providers about the most common form of eye cancer. MyUvealMelanoma tells the story of this disease, its treatment and the importance of prognostic testing, through the experience of patients who recently faced this devastating diagnosis first-hand.

15 Feb 2013

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

In 2012, The Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) jointly issued the MF Challenge Grant , seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF).

15 Feb 2013

Mallinckrodt, Actavis enter settlement agreement to resolve Exalgo patent litigation

Actavis, Inc. today announced that it has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo (Hydromorphone Hydrochloride Extended-Release) tablets.

15 Feb 2013

FDA approves Teva’s generic Adderall XR ANDA for treatment of ADHD

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for the generic version of Shire's Adderall XR Capsules, 5mg, 10mg, 15mg, 20mg, 25mg and 30 mg capsules for the treatment of attention deficit hyperactivity disorder.

14 Feb 2013

Oncology News and Research

Further Reading

Earlier may be better for neurostimulation in Parkinson’s

MILabs VECTor/CT installed by Molecular Imaging Center Antwerp (MICA) in Belgium

Scientists discover new subgroups of GC patients with different disease's characteristics

Shorter version of abPG-SGA can potentially improve outcomes for cancer patients

Colorectal cancer outcomes could be improved with regular genetic screening for Lynch syndrome

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

Overall rise in drug costs is less than in previous years

Government of Québec announces $10M investment in Personalized Medicine Partnership for Cancer

New approach could make gene therapy dramatically more effective for HIV patients

IKBKE gene plays a key role in tobacco-induced lung cancer

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

Selumetinib shrinks tumors in women with low-grade ovarian cancer

Patient-specific cancer cell lines designed to predict chemotherapy sensitivity

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Third Rock Ventures announces formation of Jounce Therapeutics

Castle Biosciences launches MyUvealMelanoma website

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

Mallinckrodt, Actavis enter settlement agreement to resolve Exalgo patent litigation

FDA approves Teva’s generic Adderall XR ANDA for treatment of ADHD

Your guide to microplate readers for cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News